Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Chief Commercial Officer At Helius Announced

Mark Morrison has been appointed Chief Commercial Officer (CCO) at Helius Therapeutics - New Zealand’s largest licenced medicinal cannabis company.

Mark Morrison

For six months prior to the appointment, he was a consultant at Helius where he developed the company’s commercial strategy. The announcement of CCO completes the executive leadership team at the headquarters of Helius in Auckland’s East Tamaki.

With significant experience in Australia, United States and New Zealand, Mr Morrison has worked in the pharmaceutical, animal health, and FMCG industries for over 25 years. He has held senior global marketing, strategic planning, new product and business development positions, and has consulted in the medicinal cannabis sector since 2018.

He has an MBA from Australia’s Macquarie Graduate School of Management, and a Bachelor of Science (Hons) from the University of Canterbury.

The Chief Executive says the Helius leadership team has highly complementary skill sets and a diversity of thinking to get the job done, with a large focus on innovation, scientific and technical prowess.

“Announcing our CCO completes our internationally-experienced team. This appointment also reinforces that after a long journey, we’re now at the business end. We’re looking forward to serving Kiwi patients, with a big eye on establishing key export markets,” says Carmen Doran, Chief Executive of Helius Therapeutics.

The 100% New Zealand-owned private biotechnology company has brought together a multi-disciplinary executive team. It has deep experience across pharmaceutical operations, cannabinoid research and development, and quality systems.

“Mark brings a broad range of experiences which Helius is already benefiting from. He understands the complex challenges of medicines manufacturing and getting highly regulated products into market. His considerable time in animal healthcare, here and the US, is also invaluable for our sister company Hale,” she says.

Helius - Auckland Building

Part-owned by Helius, Hale Animal Health has launched its own scientifically formulated range of pet supplements crafted from premium ingredients. Hale is also leading the way in developing some of the world’s first cannabinoid medicines for companion animals.

“CBD is highly effective for treating the likes of pain and inflammation in humans, and it’s no different for animals. They have an endogenous cannabinoid system just like us, meaning cannabis therapeutics work in a similar way for pets,” says Leila de Koster, Managing Director of Hale Animal Health.

Mr Morrison is excited about seeing the medicinal cannabis sector in New Zealand transitioning from an aspirational space to one of delivery.

“A key part of our commercial strategy is rolling out some comprehensive educational support for both patients and prescribers. In the coming months, we’ll be launching a number of initiatives to ensure everyone has the support and access to trusted and leading information. It’s an incredibly exciting time to be part of Helius and in fact New Zealand’s newest sector,” says Mr Morrison.

Having raised $48m in capital since 2018, Helius completed its state-of-the-art, integrated medicines manufacturing facility late last year. At 8,800sqm, it enables integrated cultivation, analytics, research, manufacturing, logistics, management, and distribution all under one secure roof.

Ms Doran believes New Zealand is poised to become an innovation hub for medicinal cannabis, with the sector representing a substantial social and economic opportunity for the country. Helius will be a key driver in the sector’s success and the first local company to undertake medicinal cannabis clinical trials.

“Helius is all about establishing and earning its position as a world leader in scientific research and development. Most importantly, our genuine care for patients and their quality of life is at the heart of everything we do. Helius has the team to deliver - and deliver big,” says Ms Doran.

The executive leadership team at Helius is Carmen Doran (Chief Executive Officer); Mary Alice Simon (Chief Operations Officer); Dr Jim Polston (Chief Science Officer); Bruce Wallace (Chief Quality Officer); Mark Woods (Chief Financial Officer); and Mark Morrison (Chief Commercial Officer).

Helius Therapeutics is the foundation sponsor of MedCan Summit 2021, which will take place on 12 and 13 October in Auckland.

helius.co.nz

 

About Helius

Helius is a focused on medicinal cannabis research, innovation, manufacturing and commercialisation. It is the country’s largest licenced producer and the first medicinal cannabis cultivator to be certified as New Zealand Grown through Buy NZ Made Campaign. The company operates a state-of-the-art, integrated facility in Auckland with indoor controlled growing systems, extraction site, an advanced cannabinoid research laboratory and manufacturing. Following changes to New Zealand’s regulatory environment, Helius is poised to set the standard for effective and accessible medicinal cannabis products in New Zealand and beyond.

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 




REINZ May Data: House Price Rises Continue; Auckland Hits New Record Median Price Again

Median prices for residential property across New Zealand increased by 32.3% from $620,000 in May 2020 to $820,000 in May 2021, according to the latest data from the Real Estate Institute of New Zealand (REINZ), source of the most complete and accurate real estate data in New Zealand... More>>

Energy Resources Aotearoa: Doubling Of Coal Use Shows Need For Local Natural Gas

New figures showing a near doubling of coal-fired electricity generation highlight New Zealand’s energy shortage and the need for natural gas as a lower carbon alternative, according to Energy Resources Aotearoa... More>>


E Tu: ‘Sense Of Mourning’ As Norske Skog Mill Set To Close

Workers at Norske Skog’s Tasman Mill now know they’ll be losing their jobs in little over a month’s time.
On Wednesday afternoon, workers were told the mill will be stopping production from the end of June... More>>



Auction: 1.4 Million In Rare Vintage Watches, Gems, Jewels & Diamonds Go Under The Hammer At Webb’s

An auction event showcasing over 1.4 Million dollars in rare jewels, gems, diamonds and vintage watches is due to take place this Sunday by Auckland based auction house Webb’s... More>>

Catalist: NZ’s New SME Stock Exchange, Gets Licence To Go Public

New Zealand has a new stock exchange – designed specifically for small and medium-sized businesses (SMEs) to raise up to $20 million a year from the public.
Called Catalist, the exchange has already been successfully working the private investment sector.... More>>

E-Commerce: Over 40% Of Those Engaged In The Bitcoin Community Are Millennials

Bitcoin has emerged to be a popular topic among millennials with digital currency increasingly being viewed as a potential source of creating wealth through investments. The interest in bitcoin by millennials signals the role this age group plays in the possible realization of the digital currency’s mass adoption... More>>